1. To evaluate the efficacy and safety of topical resveratrol 1 % gel in treatment of melasma.
2. To compare between the efficacy of topical resveratrol 1 %gel versrs chemical peeling with TCA 20% in melasma.

开始日期2025-07-22

申办/合作机构

Assiut University

CTRI/2025/04/084284

/ Not yet recruitingN/A

Safety and Effectiveness of Resveratrol in Promoting Sirtuin 1 Activation and Enhancing Health in Elderly Adults: A Prospective Interventional Approach - Nil

开始日期2025-04-20

申办/合作机构-

CTRI/2025/03/082135

/ Not yet recruiting临床2期IIT

Clinical efficacy of combined Curcumin and Resveratrol oral in-situ gels as local therapeutics in the treatment of stage I and stage II Periodontitis - NIL

开始日期2025-03-15

申办/合作机构-

100 项与白藜芦醇相关的临床结果

登录后查看更多信息

100 项与白藜芦醇相关的转化医学

登录后查看更多信息

100 项与白藜芦醇相关的专利（医药）

登录后查看更多信息

30,327

项与白藜芦醇相关的文献（医药）

2025-12-31·Emerging Microbes & Infections

Resveratrol inhibits African swine fever virus replication via the Nrf2-mediated reduced glutathione and antioxidative activities

Article

作者: Zhai, Huanjie ; Wang, Yijing ; Song, Xin ; Yao, Meng ; Cao, Mengxiang ; Liu, Di ; Li, Jia ; Qiu, Hua-Ji ; Lan, Jing ; Sun, Yuan ; Li, Lian-Feng ; Wang, Tao

African swine fever (ASF) is a highly contagious and severe infectious disease caused by African swine fever virus (ASFV). The disease significantly threatens the sustainable development of the global pig industry. Unfortunately, to date, no safe and efficacious vaccines are commercially available except in Vietnam. Antioxidative stress is a critical factor in antiviral strategies. In this study, we show that ASFV infection elevates the level of reactive oxygen species (ROS) and suppresses the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway in vitro and in vivo. Moreover, overexpressing Nrf2 can significantly inhibit ASFV replication. Through high-throughput screening of natural small molecules against ASFV, we identify resveratrol (RES), an Nrf2 activator, as a compound capable of inducing the cellular antiviral responses and effectively inhibiting ASFV replication in primary porcine alveolar macrophages (PAMs). Notably, untargeted metabolomics profiling reveals that glutathione emerges as a primary differential metabolite related to the antiviral activities of RES against ASFV. Mechanistically, RES exerts its antiviral effects and attenuates the elevated level of ROS caused by ASFV infection by inducing the production of reduced glutathione (GSH) via the activation of the Nrf2 signaling pathway. In conclusion, RES exhibits broad efficacy as a potentially effective compound for inhibiting ASFV infection and alleviating the oxidative stress induced by ASFV infection via the Nrf2 signaling pathway.

2025-12-31·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

作者: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Banerjee, Antara ; Roy, Susmita ; Deka, Dikshita ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

2025-12-31·Future Science OA

Polymeric nanoparticles-based targeted delivery of drugs and bioactive compounds for arthritis management

Review

作者: Ravindran, Selvan ; Vaidya, Anuradha ; Dixit, Tanu

This review explores the potential of polymeric nanoparticles (PNPs) as targeted drug delivery systems for arthritic treatment, overcoming the limitations of the present therapy. A thorough literature search was conducted on the databases PubMed, Scopus, and Web of Science to find published articles on the use of polymeric nanoparticles in the treatment of arthritis. This includes synthesis methods, mechanisms in drug delivery, and applications of PNPs. Polymeric nanoparticles showed excellent promise in the management of arthritis through enhanced stability of drugs, controlled and sustained drug release, and reduced systemic side effects. Some of the highlighted biocompatible and targeting capabilities of natural and synthetic polymers include chitosan, hyaluronic acid, and PLGA. Bioactive compounds such as curcumin and resveratrol delivered by PNPs enhanced therapeutic efficacy in preclinical arthritis models. Despite their promise, challenges such as rapid clearance and manufacturing scalability remain critical barriers. Polymeric nanoparticles offer a transformative approach to arthritis management by enabling targeted, sustained, and safe drug delivery. Translation into clinical applications would thus require developments in nanoparticle design, personalized medicine, and scalable production techniques.

115

项与白藜芦醇相关的新闻（医药）

2025-07-24

·PRNewswire

FDA Grants Priority Review for Addyi® (flibanserin) Paving the Way for Expanded Access to Treat Low Sexual Desire in Postmenopausal Women

Addyi is the first and only FDA-approved, hormone-free pill clinically proven to treat low sexual desire in women RALEIGH, N.C., July 24, 2025 /PRNewswire/ -- Sprout Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental application to expand the indication of Addyi® (flibanserin 100mg), the first and only FDA-approved pill for low sexual desire in women, to also include women who have gone through menopause. Continue Reading Addyi® (flibanserin) is the #1 prescribed treatment for Hypoactive Sexual Desire Disorder (HSDD). This marks a potential pivotal advancement in women's sexual health, addressing a long-standing unmet need for millions of women experiencing hypoactive sexual desire disorder (HSDD). While nearly 40% of women will experience low sexual desire at some point in their lives, women beyond their reproductive years still do not have a single FDA approved medical treatment option. "This isn't just a regulatory milestone — it's cultural recognition," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals. "Sexual desire is ageless. Access to care should be too. Priority Review brings us closer to expanding access and empowering more women with a science-backed, FDA approved solution for their sexual wellness." The FDA's Priority Review designation is reserved for drugs that offer significant improvements in treatment for serious unmet medical needs. With enhanced focus and tighter timelines granted by the Agency, this designation underscores the urgency and importance of closing the gap in women's sexual healthcare. Following the FDA's recent public meeting on removing outdated estrogen labeling, Addyi's Priority Review reflects the same urgency and momentum signaling the Agency's commitment to ensuring that women at every life stage receive evidence-based care grounded accurately with the current science and focused on improving their quality of life. Backed by the largest clinical trials in women's sexual health, Addyi originally received FDA approval for premenopausal women. After reviewing its robust safety and efficacy profile, Health Canada also approved Addyi with expanded use in women that have gone through menopause. Now the FDA has the data to potentially do the same. "This is about expanding access, expanding awareness, and expanding agency for women who have been overlooked for far too long," Eckert added. If approved, the updated Addyi label will mark a major shift toward inclusive, life-stage-spanning innovation in sexual health, recognizing that women deserve options no matter their age. About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first and only FDA-approved pill to treat low sexual desire (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve. About Addyi ® (flibanserin) Addyi is the first and only FDA-approved pill to treat low libido (HSDD) in certain premenopausal women. Addyi is a non-hormonal medication, prescribed by over 25,000 U.S. healthcare professionals and growing. Addyi works on key neurotransmitters that affect sexual response. Before taking Addyi, you should consult with your doctor about all your medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Learn more at addyi.com About Hypoactive Sexual Desire Disorder (HSDD) Hypoactive Sexual Desire Disorder (HSDD), also known as frustrating low libido, is a persistent lack of sexual interest or desire. It is the most common form of sexual dysfunction in women, impacting an estimated 40% of women according to the Mayo Clinic. IMPORTANT SAFETY INFORMATION What is the most important information I should know about ADDYI? Your risk of severe low blood pressure and fainting (loss of consciousness) is increased: if you drink alcohol close to the time you take your ADDYI dose, if you take ADDYI with certain medicines, or if you have liver problems and you take ADDYI. To lower your risk of low blood pressure and fainting (loss of consciousness): Do not drink alcohol close to the time you take your ADDYI dose Wait at least 2 hours after drinking 1 or 2 standard alcoholic drinks before taking ADDYI at bedtime. Skip your ADDYI dose if you drink 3 or more standard alcoholic drinks that evening. After taking ADDYI at bedtime do not drink alcohol until the following day. Examples of 1 standard alcoholic drink include: one 12-ounce regular beer 5 ounces of wine 1.5 ounces of distilled spirits or shot Tell your doctor about other medicines you take. Do not take or start taking any prescription or over-the-counter medicines, or herbal supplements without first talking to your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI. Do not take ADDYI if you have liver problems. If you take ADDYI and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you feel like you could faint (lose consciousness). If you faint, tell your doctor as soon as you can. Who should not take ADDYI? Do not take ADDYI if you: take certain medicines. Taking ADDYI with certain other medicines can increase the amount of ADDYI in your blood and cause severe low blood pressure, fainting (loss of consciousness), and sleepiness. Do not take ADDYI if you are taking any of the following medicines: Certain medicines used to treat HIV-1 infection Certain medicines that you take by mouth used to treat fungal infections Certain antibiotics Certain medicines used to treat Hepatitis C infection Certain medicines used to treat high blood pressure, chest pain (angina), or other heart problems Nefazodone: a medicine used to treat depression Ask your doctor or pharmacist if you are not sure if you take any of the medicines listed above. These are examples of the medicines that you should not take if you are taking ADDYI. Tell your doctor about all the medicines you take before you start taking ADDYI have liver problems are allergic to flibanserin or any of the ingredients in ADDYI. See Medication Guide for the full list of ingredients. What should I tell my doctor before taking ADDYI? Before you take ADDYI, tell your doctor about all of your medical conditions, including if you: drink alcohol, use drugs, or have a history of alcohol or drug abuse have ever had depression or other mental health problems have low blood pressure or a medical condition that can cause low blood pressure are pregnant or plan to become pregnant. It is not known if ADDYI will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if ADDYI passes into your breast milk. You and your doctor should decide if you will take ADDYI or breastfeed. You should not do both. Tell your doctor if you have had an allergic reaction such as hives, itching, or trouble breathing during or after receiving a dose of ADDYI. Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADDYI can affect the way other medicines work, and other medicines can affect the way ADDYI works, and can cause serious side effects. What should I avoid while taking ADDYI? Do not drink alcohol close to the time you take your ADDYI dose because this increases your risk of severe low blood pressure and fainting (loss of consciousness). Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take ADDYI and until you know how ADDYI affects you. Do not drink grapefruit juice if you take ADDYI. Drinking grapefruit juice during your treatment with ADDYI increases your risk of severe low blood pressure and fainting (loss of consciousness). You should not take the herbal supplements St. John's Wort, ginkgo, or resveratrol or certain over-the-counter medicines such as cimetidine until you talk to your doctor. Taking ADDYI with these herbal supplements and over-the-counter medicines may increase your risk of low blood pressure, fainting (loss of consciousness), and sleepiness. What are the possible side effects of ADDYI? ADDYI can cause serious side effects, including: Sleepiness is a common side effect of ADDYI and can be serious. Taking ADDYI can increase your risk of sleepiness if taken during waking hours, if you drink alcohol, or take certain medicines or herbal supplements. Low blood pressure and fainting (loss of consciousness) can happen when you take ADDYI even if you do not drink alcohol or take other medicines or herbal supplements. Your risk of low blood pressure and fainting (loss of consciousness) is increased if ADDYI is taken during waking hours, if you drink alcohol within 2 hours of taking ADDYI, or if you take certain medicines or herbal supplements. The most common side effects of ADDYI include: Dizziness Difficulty falling asleep or staying asleep Nausea Dry mouth Tiredness These are not all of the possible side effects of ADDYI. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. See full Prescribing Information, including Boxed Warning regarding severe low blood pressure and fainting in certain settings, and Medication Guide at addyi.com/pi. This information does not take the place of talking with your doctor. INDICATION What is ADDYI (add-ee) (flibanserin) Tablets? ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to: a medical or mental health problem problems in the relationship medicine or other drug use. ADDYI is not for use for the treatment of HSDD in women who have gone through menopause, in men or in children. ADDYI is not for use to improve sexual performance. SOURCE Sprout Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准优先审批

2025-07-23

·GlobeNewswire-Health Care

Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL™, over conventional resveratrol formulations. Unlocking Resveratrol’s Therapeutic Promise Resveratrol is one of the world’s most researched molecules and has long been studied for its powerful antioxidant, mitochondrial, and anti-inflammatory effects. However, achieving therapeutic benefit has proven elusive due to the molecule’s extremely poor bioavailability and dose-limiting gastrointestinal (GI) side effects. “Clinical studies have shown that to reach the minimum effective plasma concentration of over 250 ng/mL a patient would need to ingest approximately 5 grams of today’s marketed resveratrol products,” explained Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “At those levels, severe GI issues are nearly guaranteed, effectively halting any realistic therapeutic use.” A Pharmaceutical-Grade Breakthrough JOTROL™ was developed specifically to overcome these critical limitations. In a Phase I clinical trial, JOTROL™ achieved a nine-fold increase in bioavailability compared to traditional resveratrol, without the GI toxicity seen at high doses. This proprietary formulation enables systemic therapeutic dosing with significantly reduced pill burden and enhanced tolerability. Key Differentiators: Approximately 9 times higher bioavailability at peak plasma concentration versus naïve resveratrolNo GI side effects observed at therapeutic levelsSecured intellectual property in the U.S., EU, China, Japan, and Hong Kong through 2036Demonstrated ability to reach the central nervous system by passing the blood brain barrier, a critical factor for diseases such as Parkinson’s, Alzheimer’s, and MELAS A Platform for Clinical Development and Commercial Growth JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson’s Disease, following breakthrough preclinical data in a well-established MPTP mouse model that demonstrated meaningful improvements in motor functions. The same delivery technology is also being used in Jupiter’s Nugevia™ consumer product line, launching in Q3 2025 with targeted formulations focused on cognitive health (MND), mitochondrial energy (PWR), and skin vitality (GLO). “This is more than just a formulation. It’s a platform,” added Rosén. “Whether through pharmaceutical trials or premium consumer offerings, JOTROL™ opens entirely new pathways to address CNS diseases and longevity using the same foundational science.” Scientific Rationale: Targeting Mitochondria and Inflammation As shown in Jupiter’s preclinical and mechanistic studies, resveratrol, and by extension JOTROL™, works by promoting mitochondrial biogenesis through AMPK and SIRT1 activation. It also scavenges oxidative radicals and suppresses neuroinflammation. These mechanisms are increasingly recognized as central to the progression of neurodegenerative disease and systemic aging. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease. About Nugevia In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy. The Nugevia product line will be launched in Q3 of 2025 through the website Nugevia.com. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@redchip.com

临床1期临床2期临床结果

2025-06-09

·EINPresswire

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter’s strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia’s debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter’s proprietary JOTROL ™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. “The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “By building on the same proprietary technology platform that underpins our prescription drug development, we’re delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.” A New Standard in Evidence-Based Supplementation Nugevia’s first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL ™ , Jupiter’s enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL ™ is also the foundation of Jupiter’s ongoing therapeutic programs in Parkinson’s and Alzheimer’s disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. “We cracked the code on resveratrol’s widely published issue with bioavailability, and now we’re unlocking its potential beyond the clinic,” added Rosén. “Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.” Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter’s value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. “Nugevia represents more than a product launch—it’s a strategic engine for growth,” said Rosén. “By leveraging our core science in a consumer format, we’re creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It’s smart capital allocation with real scientific impact.” A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/ . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL ™ , is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com . About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson’s Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave Gentry RedChip Companies, Inc. 1-407-644-4256 1-800-RED-CHIP (733-2447) JUNS@redchip.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

临床1期临床2期

100 项与白藜芦醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	白藜芦醇	-	DB02709

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不孕	临床3期	西班牙	IVI Madrid SL	2018-03-13
卵巢过度刺激综合征	临床3期	西班牙	IVI Madrid SL	2018-03-13
多发性骨髓瘤	临床2期	丹麦	Sirtris Pharmaceuticals, Inc.	2009-03-30
多发性骨髓瘤	临床2期	英国	Sirtris Pharmaceuticals, Inc.	2009-03-30
痴呆	临床2期	-	Evolva Holding SA	-
帕金森病	临床2期	美国	Jupiter Neurosciences, Inc.	-
结直肠癌	临床1期	英国	GSK Plc	2008-08-19
肝转移	临床1期	英国	GSK Plc	2008-08-19
乳酸性酸中毒	临床1期	美国	Jupiter Neurosciences, Inc.	-
阿尔茨海默症	临床1期	美国	Protheragen, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03743636 (NICE, CTgov)	临床3期	外周动脉疾病	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	廠膚選蓋獵淵鹽廠鹹網(壓蓋艱獵憲醖淵積醖繭) = 廠膚鹹網獵鹽鑰遞艱襯淵選觸構鬱鬱齋窪顧鬱 (構鬱廠膚積蓋淵積膚觸, 7.84) 更多	-	2025-01-14
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	廠膚選蓋獵淵鹽廠鹹網(壓蓋艱獵憲醖淵積醖繭) = 糧遞範艱齋網顧襯壓積淵選觸構鬱鬱齋窪顧鬱 (構鬱廠膚積蓋淵積膚觸, 8.69) 更多
NCT03597568 (Resveratrol and Vascular Function in CKD, Pubmed)	N/A	糖尿病 \| 慢性肾病	-	Resveratrol supplementation	衊醖淵鏇夢鹽鹽鹹夢淵(衊襯蓋顧繭繭觸糧艱憲): ratio of geometric mean changes = 1.43 (95% CI, 1.15 ~ 1.77), P-Value = 0.001	积极	2024-02-01
				Placebo
NCT02123121 (REVIVE, CTgov)	临床2期	-	60	Vegetable cellulose (Vegetable Cellulose)	齋鑰顧艱築壓製築鹽艱(顧繭鏇膚衊鬱遞鏇鑰觸) = 壓構繭積淵壓襯鹽廠膚糧鏇積膚積鬱淵鹹襯選 (願餘壓顧糧選夢餘夢淵, 壓鹽衊醖遞窪積襯觸鏇 ~ 願觸獵醖廠憲蓋願壓觸) 更多	-	2023-07-27
				All groups+Resveratrol 1000 mg/day (Resveratrol 1000 mg/Day)	齋鑰顧艱築壓製築鹽艱(顧繭鏇膚衊鬱遞鏇鑰觸) = 獵齋壓醖製繭餘構鏇簾糧鏇積膚積鬱淵鹹襯選 (願餘壓顧糧選夢餘夢淵, 觸製範憲夢齋築鑰網壓 ~ 鏇願觸夢網顧簾艱窪艱) 更多
ARVO2023	临床2期	地图样萎缩	12	Resveratrol, Quercetin, and Curcumin (RQC)	鬱衊憲遞觸積夢簾遞網(鏇鹹襯選廠鑰衊壓齋艱) = 鹽襯壓鑰遞積網糧獵廠遞選窪簾網製鑰網蓋鬱 (構淵窪壓觸構網鹽鏇範, 0.35)	-	2023-06-01
NCT04400890 (CTgov)	临床2期	新型冠状病毒感染	105	Vitamin D3+Resveratrol (Resveratrol With Vitamin D3)	積糧積鹹憲醖獵願夢積 = 憲糧築糧廠窪選齋壓衊淵齋膚積餘積齋膚壓鏇 (簾築鬱憲繭鹽網鹽選襯, 鏇鹹襯願鏇網艱遞積餘 ~ 艱醖鬱簾齋構顧網鹹淵) 更多	-	2023-02-24
				Vitamin D3 (Placebo With Vitamin D3)	積糧積鹹憲醖獵願夢積 = 繭膚廠蓋選顧艱淵製製淵齋膚積餘積齋膚壓鏇 (簾築鬱憲繭鹽網鹽選襯, 鹽鹽選壓鹽積壓獵繭觸 ~ 遞鏇獵憲淵鑰顧願積鹹) 更多
NCT04867252 (Pubmed \| Endocrine)	临床2期	多囊卵巢综合征	88	Metformin and Pioglitazone	範願淵顧積獵醖齋餘艱(糧襯選網製齋選鑰範鹽) = 遞齋醖遞鏇簾範艱選襯顧獵鏇窪蓋鬱廠鑰鬱構 (製淵夢醖廠鑰衊廠壓繭 )	积极	2022-09-28
				Resveratrol and Myoinositol	範願淵顧積獵醖齋餘艱(糧襯選網製齋選鑰範鹽) = 觸網觸觸遞夢簾夢範醖顧獵鏇窪蓋鬱廠鑰鬱構 (製淵夢醖廠鑰衊廠壓繭 )
NCT04668274 (CTgov)	临床1期	-	24	200 mg resveratrol as JOTROL (Part 1: JOTROL (Resveratrol) 200 mg (Treatment A))	壓鑰壓襯齋製衊壓鏇獵 = 蓋淵夢鬱醖鹹網選鬱積廠鏇鹹鑰膚構艱鑰廠選 (鏇衊鏇淵鏇網夢積選願, 醖衊範廠鹹膚夢製餘範 ~ 壓糧糧衊窪選選鏇觸網) 更多	-	2022-08-12
				500 mg resveratrol as JOTROL (Part 1: JOTROL (Resveratrol) 500 mg (Treatment B))	壓鑰壓襯齋製衊壓鏇獵 = 網餘鹹願觸簾鹹選繭繭廠鏇鹹鑰膚構艱鑰廠選 (鏇衊鏇淵鏇網夢積選願, 積餘獵憲醖衊窪醖鬱艱 ~ 鏇範鹽餘觸膚艱衊艱膚) 更多
NCT04400890 (Pubmed)	临床2期	新型冠状病毒感染	105	Resveratrol	獵淵構齋夢餘餘膚廠簾(壓夢繭齋艱艱鑰窪膚鬱) = 壓構顧壓淵艱窪鏇壓鬱糧鹹壓構壓範鏇繭鹽淵 (範顧衊醖製廠齋簾鹽憲 ) 更多	积极	2022-06-29
				Placebo	獵淵構齋夢餘餘膚廠簾(壓夢繭齋艱艱鑰窪膚鬱) = 蓋獵醖膚網蓋遞壓醖鏇糧鹹壓構壓範鏇繭鹽淵 (範顧衊醖製廠齋簾鹽憲 ) 更多
NCT01354977 (CTgov)	临床2期	2型糖尿病 \| 胰岛素抵抗 \| 炎症	20	Resveratrol	蓋積艱製窪構選壓獵衊(衊顧願繭廠窪鏇夢鏇觸) = 網構齋遞積鹹膚膚蓋築鹹積鹹鏇醖齋鹹糧淵壓 (築積網鑰衊淵鑰觸淵選, 1.709) 更多	-	2022-03-08